NCT07078838View on ClinicalTrials.gov

Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

March 31, 2029

Study Completion Date

March 31, 2029

Conditions
Endometrial CancerEndometrial Intraepithelial NeoplasiaGrade 1 Endometrial Endometrioid Carcinoma
Interventions
DRUG

Tirzepatide

Patients will receive a subcutaneous dose of 5 mg weekly for the 4 weeks prior to surgical staging.

Trial Locations (1)

27599

Lineberger Comprehensive Cancer Center, Chapel Hill

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

UNC Lineberger Comprehensive Cancer Center

OTHER